Improved HDAC Inhibition, Stronger Cytotoxic Effect and Higher Selectivity against Leukemias and Lymphomas of Novel, Tricyclic Vorinostat Analogues

• Main Authors: Bartosz Bieszczad (Author), Damian Garbicz (Author), Marta Świtalska (Author), Marta K. Dudek (Author), Dawid Warszycki (Author), Joanna Wietrzyk (Author), Elżbieta Grzesiuk (Author), Adam Mieczkowski (Author)
• Format: Book
• Published: MDPI AG, 2021-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Histone deacetylase (HDAC) inhibitors are a class of drugs used in the cancer treatment. Here, we developed a library of 19 analogues of Vorinostat, an HDAC inhibitor used in lymphomas treatment. In Vorinostat, we replaced the hydrophobic phenyl group with various tricyclic 'caps' possessing a central, eight-membered, heterocyclic ring, and investigated the HDAC activity and cytotoxic effect on the cancer and normal cell lines. We found that 3 out of the 19 compounds, based on dibenzo[<i>b,f</i>]azocin-6(5<i>H</i>)-one, 11,12-dihydrodibenzo[<i>b,f</i>]azocin-6(5<i>H</i>)-one, and benzo[<i>b</i>]naphtho[2,3-<i>f</i>][1,5]diazocine-6,14(5<i>H</i>,13<i>H</i>)-dione scaffolds, showed better HDACs inhibition than the referenced Vorinostat. In leukemic cell line MV4-11 and in the lymphoma cell line Daudi, three compounds showed lower IC₅₀ values than Vorinostat. These compounds had higher activity and selectivity against MV4-11 and Daudi cell lines than reference Vorinostat. We also observed a strong correlation between HDACs inhibition and the cytotoxic effect. Cell lines derived from solid tumours: A549 (lung carcinoma) and MCF-7 (breast adenocarcinoma) as well as reference BALB/3T3 (normal murine fibroblasts) were less susceptible to compounds tested. Developed derivatives show improved properties than Vorinostat, thus they could be considered as possible agents for leukemia and lymphoma treatment.

Item Description

10.3390/ph14090851
1424-8247